MWN109 oral / Minwei Biotech - LARVOL DELTA

Lepu Medical subsidiary Minwei Biotech's Phase I clinical trial data in China for its triple agonist MWN109 injection and oral tablets showed positive results. [Google translation] (Sina Corp) - "Data shows that both dosage forms demonstrated good safety and tolerability in their respective trials, and exhibited significant efficacy in weight loss. Specifically, in the Phase Ib trial of MWN109 injection in China, after 14 weeks of continuous administration to non-diabetic overweight/obese participants, the treatment group showed a maximum mean weight loss relative to baseline of 16.67%, significantly better than the 0.99% in the placebo group. Its Phase Ia trial also showed a maximum mean weight loss of 3.49% after a single dose, reaching 8.37% after multiple doses. In a Phase I trial in China, MWN109 oral tablets, administered once daily for four weeks, resulted in a mean weight loss of 4.18% to 7.82% within a dose range of 7.5 mg to 45 mg, demonstrating a dose-response relationship and showing better results than the placebo group."

P1 data • Obesity